Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Army Researchers Fighting Ebola on the Front Lines

    By Global Biodefense StaffAugust 25, 2014
    USAMRIID Ebola Laboratory
    A technician sets up an assay for Ebola within a containment laboratory. Samples are handled in negative-pressure biological safety cabinets to provide an additional layer of protection. Credit: U.S. Army photo by Dr. Randal J. Schoepp
    Share
    Facebook LinkedIn Reddit Email

    Army researchers are working on developing vaccines for the deadly Ebola virus, as well as combating the spread of the virus and caring for those who are infected. The virus has recently killed more than 800 in Sierra Leone, Guinea and Liberia.

    One of these researchers is Dr. Randal J. Schoepp, a diagnostics specialist and chief of the Applied Diagnostics Branch, U.S. Army Medical Research Institute of Infectious Diseases, known as USAMRIID.

    Schoepp spoke by telephone from Monrovia, Liberia, with WAMU radio talk show host Kojo Nnamdi about efforts to fight the deadly Ebola outbreak in West Africa.

    Colleagues at USAMRIID, along with researchers from Public Health Canada, helped develop the serum given recently to two U.S. medical workers, Dr. Kent Brantly and Nancy Writebol, who contracted the virus while working with patients infected by Ebola in West Africa, Schoepp said.

    The serum is “basically a cocktail of three humanized, monoclonal antibodies produced in tobacco plants,” he said. Humanized, monoclonal antibodies are derived from animals whose protein sequences have been altered to more closely resemble those produced by humans.

    Initially, the researchers looked at six antibodies. Three of the most promising were then down-selected, he said, and were tested on non-human primates at various concentrations and time periods throughout their infections. The results of the studies showed that when these antibodies were administered in the final, most advanced stages of Ebola, the primates recovered.

    “That’s huge in our field,” he said. If the two Americans recover, the next step for researchers is to develop clinical trials, he said, adding that it’s way too early to make conclusions about the efficacy of the treatment.

    Schoepp has been working in West Africa for a number of years on diagnostics for other viruses. In 2006, he conducted research on Lassa Fever in Sierra Leone. Like Ebola, it is a viral hemorrhagic fever, meaning that one of the symptoms is bleeding caused by damage to the vascular system.

    Lassa differs from Ebola in that it predictably occurs in about the same time every year, he said, with about 500 to 700 cases. But Schoepp found that of those cases, only 30 to 40 percent were Lassa. So he began to study the 60 to 70 percent that were not and found that they were closely related to the Zaire strain of Ebola.

    Since Schoepp’s diagnostics research on the Zaire strain has been carried out for a number of years, he said he’s hopeful some of that will be useful in studying the West African Ebola. Working in West Africa is particularly challenging, he explained. “We have to bring almost everything with us,” he said. “When we arrived here in Liberia, we had to set up the entire laboratory, train the staff and then supervise them as they help fight the disease in their own country.”

    Diagnostics, Schoepp’s specialty, is detective-like work. The strategy involves using a molecular assay such as PCR, or Polymerase Chain Reaction, that looks for particular signatures in the genome of the virus, he explained. Another approach, he said, involves the use of immunodiagnostics to detect either the virus or detect the antibodies in an infected person. He credits USAMRIID with testing some of the early antibodies IgM, or Immunoglobulin M, and the later antibodies IgG, or Immunoglobulin G, which appear after the Ebola virus attacks.

    Researchers at USAMRIID are “trying to continue to improve on those assays to make them easier and more specific and sensitive,” he added. One of the biggest hurdles to fighting the Ebola virus, he said is not medical, but rather cultural.

    Most who contract Ebola get it when preparing the bodies of loved ones for burial. “In Africa and other regions of the world it’s traditional to wash the body, to caress the body, to kiss the body,” he said. In some of the more isolated societies, people even drink the blood of the dead as a way to honor them, he added.

    So these practices “are leading to an increase in the number of infections we’re seeing,” he said. These cultural practices are “very delicate to deal with in West African societies. You have to tread very lightly and bring it to them in a way they’ll understand so they consider changing those practices. We haven’t made it to that point yet. That’s why we’re seeing this outbreak continue.”

    Source: Article courtesy of David Vergun, ARNews

    Image: A technician sets up an assay for Ebola within a containment laboratory. Samples are handled in negative-pressure biological safety cabinets to provide an additional layer of protection. Credit: U.S. Army photo by Dr. Randal J. Schoepp

    Ebola
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense News Headlines of the Week – August 24, 2014
    Next Article OMRF Awarded 14.5M for Anthrax Studies

    Related Stories

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    APHIS Announces Funding for Tribes to Support Animal Disease Preparedness and Response

    October 24, 2023

    USDA APHIS Announces Partnership to Improve Early Detection of Emerging Animal Diseases

    October 17, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.